AVEG 004

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (GP160) of Human Immunodeficiency Virus

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) December 13, 1990
gp160 Vaccine (Immuno-AG) Protein gp160 env B LAI, MN
gp160 Vaccine (Immuno-AG) Protein
USA 60